- RecruitingPHASE3
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
This study is looking at the long-term effects of a medicine called eptinezumab in children and teenagers (aged 6 to 17) who experience migraine headaches. It's for those who have already taken part in a previous migraine study with this medication.
For: MigraineUnited States · Argentina · Canada - RecruitingPHASE3
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
This study is testing a new medicine, eptinezumab, for young people aged 12 to 17 who get chronic migraines. It wants to see if this medicine can reduce the number of migraine days compared to a dummy treatment.
For: Chronic Migraine in ChildrenUnited States · Argentina · Canada - RecruitingPHASE3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
This study is looking into a new medicine called eptinezumab to see if it can help children and teenagers aged 6 to 17 reduce how often they get episodic migraines. Researchers want to know if it makes a real difference compared to a dummy treatment.
For: Episodic MigraineUnited States · Argentina · Canada